Carboplatin 10 mg/ml Intravenous Infusion
Sponsors
AbbVie Deutschland GmbH & Co. KG, F. Hoffmann-La Roche AG, Janssen - Cilag International, Genmab A/S, Amsterdam UMC
Conditions
Advanced or Metastatic Non-Squamous NSCLCEGFR Exon 20ins Mutated Locally
Advanced or Metastatic Non-Small Cell Lung CancerEarly-Stage Resectable Non-small cell lung cancer (NSCLC)Locally Advanced or Metastatic Non-Small Cell Lung CancerMalignant solid tumors: endometrial carcinoma (EC)Newly diagnosed with an intracranial or spinal ependymoma (all WHO grades) including ependymoma variants: cellularUntreated Metastatic Non-Squamous Non-Small Cell Lung Cancerclear-cell and tanycytic or anaplastic ependymoma.
Phase 1
First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors
Active, not recruitingCTIS2023-509059-15-00
Start: 2019-04-30Target: 295Updated: 2026-01-16
An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination with Budigalimab in Advanced or Metastatic Non-Squamous NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations (AndroMETa-Lung-536)
RecruitingCTIS2024-514465-18-00
Start: 2025-04-23Target: 105Updated: 2025-11-27
Phase 2
Multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 prior line of platinum-based chemotherapy
RecruitingCTIS2022-501220-14-00
Start: 2023-10-17Target: 45Updated: 2025-12-10
A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) – LIVIGNO-4
RecruitingCTIS2023-505773-32-00
Start: 2025-03-25Target: 57Updated: 2025-11-21
Liposomal iRInotecan, Carboplatin or oXaliplatin in the first line treatment of esophagogastric cancer: a randomized phase 2 study (LyRICX)
Active, not recruitingCTIS2023-509287-26-00
Start: 2019-07-01Target: 322Updated: 2025-11-04
SIOP Ependymoma Program II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependymoma
RecruitingCTIS2024-512222-28-00
Start: 2015-06-02Target: 876Updated: 2024-12-09
Phase 3
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in
Combination with Platinum-Based Chemotherapy Compared with Platinum-Based
Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-
Small Cell Lung Cancer After Osimertinib Failure
Active, not recruitingCTIS2023-506518-33-00
Start: 2021-11-10Target: 259Updated: 2025-11-13
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Active, not recruitingCTIS2023-506033-29-00
Start: 2020-10-09Target: 64Updated: 2025-12-17
A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients With resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
CompletedCTIS2023-504209-35-00
Start: 2018-04-04End: 2025-12-31Target: 207Updated: 2026-01-13